Afacifenacin

Drug Profile

Afacifenacin

Alternative Names: Afacifenacin fumarate; NS-986; SMP-986

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Nippon Shinyaku; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Class Piperidines; Quinazolinones; Small molecules; Urologics
  • Mechanism of Action Muscarinic receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nocturia
  • No development reported Overactive bladder

Most Recent Events

  • 29 Jul 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Japan, European Union (PO)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 13 May 2014 Phase-II clinical trials in Nocturia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top